Towa 2B
B2B
Worldwide
We operate worldwide. We are already present in more than 30 countries through our strategic alliances.
We develop and manufacture high-quality generic medicines for pharmaceutical companies and distributors who share our values, our patient-oriented approach and a high level of rigor, quality, safety and efficacy.
We apply two formulas: out-licensing and distribution. Manufacturing and development are mainly carried out in-house.
During 2023 we consolidated our CDMO unit with which we want to be able to offer our partners the possibility to collaborate thanks to our extensive production capacities in Barcelona.
At Towa 2B, we focus on building long-term, value-driven relationships, helping our partners grow while contributing to people’s health.
Our presence
Towa CMO/CDMO
We expanded our commitment to health through: Towa CMO/CDMO. Backed by decades of pharmaceutical experience and robust industrial capabilities, we now offer our production and/or R&D potential to other generic and/or innovative companies in the pharmaceutical sector to develop and manufacture their medicines.
Our production plant in Barcelona, covering more than 35,000 m², is one of the largest in Europe. Equipped with cutting-edge technology and compliant with the highest quality and international regulatory standards, it ensures efficiency, flexibility, and fast time-to-market. Our R&D center and pilot plant have also acquired a fundamental role, becoming the center of excellence for our company’s parent company, Towa Pharmaceutical. With an annual production capacity exceeding 34.5 billion units, our output continues to grow steadily year after year.
Explore our production plant through an immersive virtual tour.
We work closely with our partners to turn projects into reliable treatments, combining scientific rigor with customer-centric flexibility.